IFOPA Leadership Develops Guidelines for Engaging Pharmaceutical Companies
New document is intended to define a preferred partnership approach and ensure IFOPA’s independence as a patient organization
Read moreYahtzee is a Good Friend
Miriam Rocke’s service dog fills several roles in her life
“He’s almost 7, but he still acts like a puppy,” says Miriam Rocke. “He does that ‘I have something in my mouth’ walk when he wants to show off.”
Read moreLetter Writing Campaign in honor of Natalie
Effective grassroots fundraising
Read moreOpportunity for New Patients to Enroll in Palovarotene Study
Please read Clementia's Clinical Program Announcement: Opportunity for New Adult and Older Adolescent Subjects to Enroll in Palovarotene Study. Click here.
Celebrating One Year of Making a Difference
The FOP Registry is celebrating one year of making a difference today!
Read moreIFOPA's Support of Clinical Trials
A Message about the IFOPA's Support for Clinical Trials
Read moreRegeneron's Work in FOP
The International FOP Association is pleased to share the following news from Regeneron Pharmaceuticals
Regeneron is pleased to inform you that anti-Activin A antibody, REGN2477, is now in a clinical trial.
Read moreA Remarkable Record of Service – And An Important Transition
Thank you for your commitment!
Still active in the FOP community, Dr. Pignolo has a accepted a new position.
Read moreNext Step in Clementia's Clinical Program for FOP
Enrollment information and FAQs
The IFOPA is pleased to share the announcement and new FAQs from Clementia Pharmaceuticals regarding the palovarotene clinical trial.
Read more